

PC/4-32711A

1 of 1
AM

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
26 August 2004 (26.08.2004)

PCT

(10) International Publication Number
WO 2004/072301 A1

(51) International Patent Classification⁷: **C12Q 1/68**

(74) Agent: **GODDARD FOOTE, Harrison**; 31 St Saviourgate, York YO1 8NQ (GB).

(21) International Application Number:
PCT/GB2004/000193

(22) International Filing Date: 21 January 2004 (21.01.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0303497.2 15 February 2003 (15.02.2003) GB

(71) Applicant (for all designated States except US): **THE UNIVERSITY OF LIVERPOOL** [GB/GB]; Senate House, Abercromby House, Liverpool L69 3BX (GB).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MCCREAVY, David, Thomas** [GB/GB]; The University of Liverpool, New Medical School Building, Ashton Street, Liverpool L69 3GE (GB). **FRASER, William, Duncan** [GB/GB]; The University of Liverpool, New Medical School Building, Ashton Street, Liverpool L69 3GE (GB). **GALLAGHER, James, Anthony** [GB/GB]; The University of Liverpool, New Medical School Building, Ashton Street, Liverpool L69 3GE (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— with international search report


[Continued on next page]

(54) Title: IMMUNO-PCR METHOD

Templates

Specific templates anneal to the antibody 3' regions of the labels.

Templates are highly conserved differing only by a few bases.



(57) Abstract: We describe a variation of an immunoassay which utilises the polymerase chain reaction to detect a plurality of biological molecules in a sample. The method employs a plurality of nucleic acid templates whose annealing temperature to a detectable probe varies.

WO 2004/072301 A1

WO 2004/072301 A1



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

IMMUNO-PCR METHOD

The invention relates to an immunoassay which utilises the polymerase chain reaction to detect a plurality of biological molecules in a sample.

5

A diagnostic test has to have a very high degree of sensitivity and specificity if it is to have value in predicting the early onset of disease. There are a number of molecules present within serum, for example, interleukins and parathyroid hormone related protein, which are potential markers of cancer and other pathological conditions.

10 Currently these are only measurable during the late stages of the disease process when they are overexpressed by tumours. Under normal conditions the proteins are present at concentrations $<0.1\text{pM}$. Moreover, the early detection of pathogenic organisms in an infection can be critical to whether or not an infected animal survives the infection. This is particularly the case in diseases such as bacterial meningitis and septicemia
15 caused, for example by *Staphylococcus aureus*. The earlier these molecules can be measured during the disease process the better the prognosis. However, early detection means that the molecules are at low concentrations and the signaling/quantitation systems of current immunoassays, using enzymes and chemiluminescence does not provide sufficient sensitivity to measure at these low
20 levels.

In addition, there are many clinical scenarios where the simultaneous measurement of more than one biological molecule in a sample would be of significant diagnostic and therapeutic benefit. Some obvious examples relate to the investigation of endocrine
25 abnormalities where the interpretation of a single result would be significantly affected by another result.

In thyroid disease a combination of thyroid stimulating hormone (TSH) with an index of thyroid hormone status (total or free thyroid hormone) is essential to make an
30 accurate diagnosis in many cases. In investigation of calcium disorders a combination of Parathyroid Hormone (PTH) and Parathyroid Hormone Related Protein (PTHrP) would differentiate the two major causes of hypercalcaemia and elucidate the presence of dual pathology which is often overlooked. When problems of sexual dysfunction and infertility are investigated the pituitary hormones luteinising hormone

(LH) and follicle stimulating hormone (FSH) are measured with oestradiol and/or testosterone included in the hormone profile. Another major diagnostic area is the screening for Down's syndrome where a combination of hormone measurements (Human Chorionic Gonadotrophin (HCG), alpha feto-protein (α FP) and maternal age
5 is used to assess risk of the fetus having Down's syndrome. It is clear that the development of an assay system able to simultaneously measure a number of analytes would have numerous diagnostic applications.

Immuno-PCR is a method which combines both antibody technology and the
10 polymerase chain reaction or other means to detect a nucleic acid probe conjugated to the antibody. In essence, immuno-PCR utilises an antibody to which a nucleic acid probe has been conjugated. The conjugate binds an antigen to be detected via the antibody part and non-bound conjugate is washed from the sample. The bound antibody is then detected by a PCR reaction which amplifies the nucleic acid part of
15 the conjugate. The assay provides a sensitive and specific test for a biological molecule with specificity being provided by the antibody and sensitivity by the PCR detection of the nucleic acid conjugated to the antibody. We disclose a variation on the immuno-PCR method, referred to as Multiple Analyte Quantitation through Single Stranded Extension (MAQSSE), which is described in WO 03/048388, the contents of
20 which are herewith incorporated by reference.

Briefly, WO 03/048388 discloses the use of a single stranded DNA reporter molecule as a means of detecting a ligand/DNA conjugate which is bound to a target molecule the detection of which is desired. This method is referred to as Multiple Analyte
25 Quantitation through Single Stranded Extension (MAQSSE).

An oligonucleotide is conjugated to a ligand which has specificity for a biological molecule. The ligand/DNA conjugate is incubated with a sample and binds a target biological molecule. A single stranded DNA template (ssDNA) of defined length is
30 then added to the reaction and anneals to the bound oligonucleotide. A DNA polymerase and deoxynucleotide triphosphates are added and the reaction incubated to elongate the primed oligonucleotide strand to produce a dsDNA. A nuclease specific for ssDNA is added to the reaction to degrade the background ssDNA.

template, resulting in no detectable background template. To generate a measureable signal, PCR is undertaken to amplify the double stranded DNA followed by detection.

5 A variation of this method is also disclosed in WO 03/048388 which simplifies the method and avoids the addition of an exogenous nuclease to digest ssDNA which is not bound to the conjugate/biological molecule complex. The variation comprises a ligand:oligonucleotide conjugate wherein the oligonucleotide has a bipartite sequence structure. The conjugate thus formed is contacted with a test sample which potentially includes a biological molecule to which the ligand binds. The bound conjugate is then
10 incubated with the ssDNA template. The bipartite oligonucleotide is able to anneal over part of its length to a region of the ssDNA. The annealed bipartite oligonucleotide is extended by DNA polymerase to form a double stranded DNA. An excess of oligonucleotide primer is added to the reaction mix, the sequence of which is able to anneal to that part of the bipartite oligonucleotide which is not annealed to
15 the ssDNA template. A polymerase chain reaction is then conducted. Only the ssDNA which has annealed to the bipartite oligonucleotide is capable of being subsequently amplified therefore the assay provides a highly specific and sensitive means to monitor the presence of biological molecules. Preferably the bipartite oligonucleotide comprises a palindromic sequence. The use of primers which are
20 palindromes of one another (i.e. a palindromic sequence is a sequence which has the same sequence when read in a 5' - 3' direction as when read in a 3' - 5' direction. For example a palindrome of the sequence: 5' GGGCAAACGGG 3' is 3' GGGCAAACGGG 5') decreases background noise and allows accurate PCR conditions to be established thereby providing an reliable test.

25

We have further adapted the above method to provide a means to simultaneously measure a plurality of biological agents in a single sample in a single reaction mixture. The invention utilises melt curve analysis to facilitate the detection.

30 The relative thermostability or T_m of a polynucleotide depends primarily upon its guanine (G) and cytosine (C) content. T_m is also influenced, although to a lesser extent, by the length of the nucleotide sequence and the distribution of G + C. For example so called GC clamps at the end of a polynucleotide sequence can increase T_m without increasing the overall G + C content. The detection and comparison of DNA

sequences based on melting temperature is known to those skilled in the art. These methods can generally be categorised into three different types. Firstly, measuring a signal from a specifically bound reporter molecule which indicates the presence or absence of a polynucleotide sequence. Secondly, and as outlined in JP 3-147796A, a melt curve is generated as an indicator of the presence or absence of a polynucleotide sequence. Thirdly, a method whereby melt curves are compared, each melt curve being characteristic of a distinct polynucleotide sequence.

We have developed a series of ssDNA reporter molecules of differing T_m which allows a plurality of biological molecules to be detected in a single sample. The method is schematically illustrated in Figure 7a-h. By applying melt curve analysis to identify specific amplified PCR labels through differences in annealing of a common pair of probes to the templates. Each template/probe interaction will have a specific T_m and through melt curve analysis the area under the curve can be measured to determine the concentration of the template.

According to an aspect of the invention there is provided an immuno polymerase chain reaction method to detect a plurality of biological molecules in an isolated sample comprising: providing a sample to be tested and a preparation including a plurality of ligands wherein said ligands are conjugated or associated, directly or indirectly, with an oligonucleotide molecule(s); a plurality of nucleic acid template molecules adapted to anneal to said oligonucleotide molecule(s) and at least one detectable probe molecule adapted to anneal to said template molecule wherein said template molecule(s) comprise a nucleic acid sequence which is modified by addition, deletion or substitution of at least one nucleic acid base wherein said modifications provide a plurality of templates which vary from one another such that the annealing temperatures of said templates to at least one detectable probe molecule is varied.

According to an aspect of the invention there is provided an immuno polymerase chain reaction method to detect a plurality of biological molecules in a sample wherein said method comprises the steps of:

- i) providing a preparation comprising;
 - a) an assay sample to be tested; and

- b) a plurality of ligands specific for at least one biological molecule in said assay sample wherein each ligand is coupled to an oligonucleotide;
- ii) incubating said preparation under conditions which allow the binding of said ligands to said biological molecules to form a complex;
- 5 iii) adding to the first preparation a second preparation comprising;
- c) a plurality of single stranded nucleic acid templates wherein said template molecules comprise a nucleic acid sequence which is modified by addition, deletion or substitution of at least one nucleic acid base wherein said modifications provide a plurality of templates
- 10 which vary from one another such that the annealing temperatures of said templates to at least one complementary detectable probe molecule is varied and which at least part of said template is adapted to anneal to the oligonucleotide of (b); and
- d) at least one oligonucleotide primer and polymerase chain reaction
- 15 reagents;
- iv) conducting a polymerase chain reaction to amplify said template; and
- v) conducting melt curve analysis during said reaction to determine the presence of said biological molecule.
- 20 In a preferred method of the invention there is provided an assay sample selected from the group consisting of a sample of: blood; serum; semen; lymph fluid; cerebrospinal fluid; tears; saliva; urine; sweat. The assay sample may be an environmental sample, for example soil or water.
- 25 More preferably said method is for use as a diagnostic tool in clinical situations where the simultaneous measurement of more than one analyte would be of significant diagnostic and therapeutic benefit, for example in the investigation of endocrine abnormalities.
- 30 In a further preferred method of the invention said ligands are polypeptides.

In a yet further preferred method of the invention said polypeptides are antibodies, or at least the effective binding part thereof. Preferably said antibodies are monoclonal antibodies, or at least the Fab fragment of said monoclonal antibody.

In a further preferred method of the invention said ligands are receptors.

5 In a further preferred method of the invention said biological molecules are associated with a disease condition, for example cancer (e.g. a tumour rejection antigen). Tumour rejection antigens are known in the art, for example and not by way of limitation, the MAGE, BAGE, GAGE and DAGE families of tumour rejection antigens, see Schulz et al Proc Natl Acad Sci USA, 1991, 88, pp991-993.

10 In a further preferred method of the invention said biological molecule is an antigenic polypeptide expressed by a pathogen. For example a viral, bacterial or parasitic pathogen.

15 It will be clear to one skilled in the art that the ligands can be antibodies which are specific for a biological molecule which may be present in said assay sample. Alternatively the biological molecule may be labelled with the oligonucleotide and the antibody specific for said biological molecule detected in the assay sample.

20 In a further preferred method of the invention each single stranded nucleic acid templates comprise a conserved nucleic acid sequence each of which is modified by addition, deletion or substitution of at least one nucleic acid base wherein said modifications provide a plurality of probes which vary from one another such that the annealing temperatures of said probes to a complementary sequence is varied. It is well established in the art that methods are available to manufacture nucleic acids of
25 defined sequence and base composition.

Preferably still the annealing temperatures of said templates for said detectable probe is in a range of between 40 to 80°C. More preferably still, said annealing temperatures are in the range of between 50 to 70°C.

30

It will be apparent that the skilled person can readily design probes of defined nucleotide sequence which vary from one another in annealing temperature for a given template under defined hybridisation conditions, see Sambrook et al Molecular Cloning, A laboratory Manual, 1989.

In a further preferred method of the invention said detectable probe is a fluorescently labelled probe, preferably a pair of fluorescently labelled probes and detection is via fluorescence resonance energy transfer.

5

FRET is a distance-dependent interaction between the electronic excited states of two dye molecules in which excitation is transferred from a donor molecule to an acceptor or quencher molecule whilst returning the donor molecule to its lower energy level or ground state without fluorescence emission.

10

In a further preferred method of the invention said oligonucleotide primer comprises a palindromic sequence.

A palindromic sequence is a sequence which has the same sequence when read in a 5' – 3' direction as when read in a 3' – 5' direction. For example a palindrome of the sequence: 5' GGGCAAACGGG 3' is 3' GGGCAAACGGG 5'. The use of a single palindromic primer to amplify the ssDNA allows accurate PCR conditions to be established thereby providing a reliable test.

20 According to a further aspect of the invention there is provided a preparation comprising a plurality of single stranded nucleic acid template molecules wherein said molecules comprise a nucleic acid sequence which is modified by addition, deletion or substitution of at least one nucleic acid base wherein said modifications provide a plurality of templates which have altered annealing temperatures for at least one
25 complementary single stranded nucleic acid molecule capable of annealing to said template.

In a preferred embodiment of the invention said composition further includes at least one complementary detectable probe molecule. Preferably said probe includes at least
30 one fluorescent label.

According to a further aspect of the invention there is provided a kit comprising: a plurality of ligands; oligonucleotide molecules; a plurality of nucleic acid templates;

and a detectable probe molecule(s). Optionally said kit includes polymerase chain reaction reagents.

5 An embodiment of the invention will now be described by example only and with reference to the following figures:

Figures 1, 2, 3, 4, 5, and 6 illustrate oligonucleotide probes used in the method of the invention; and

10 Figure 7a-h is a schematic representation of the use of melt curve analysis to detect a plurality of biological molecules;

Materials and Methods

15

(i) Label Design Procedure

pcDNA3.1v5histopo.seq (Invitrogen) was loaded into Oligo6,

20 Two primer pairs (in bold) were chosen see Figure 1

The forward sequences were appended to the 5' region of the Rev sequences, to create palindromic binding sites see Figure 2

25 FrameworkLabel03 was produced by replacing the appended forward sequence of FrameworkLabel02 with that of FrameworkLabel01, see Figure 3

30 Insert labels were designed to replace the nnnnnn region and consisted of two binding sequences one termed the sensor and the second the anchor. MeltCalc software was used to design two sensor sequences differing in respect to one base G-C whose T_m differed by over 10°C. The anchor primer was labelled at the 3' with fluorescein. The anchor was designed to bind from four bases downstream and be labelled with LC 640 at its 5' end thereby facilitating FRET when both were simultaneously bound, see Figure 4.

nnnn sequences in the Frameworklabel01 and 03 were replaced by InsertLabel01 see Figure 5 and InsertLabel02 respectively see Figure 6

5 (ii) Conjugation of labels to Monoclonal Antibody

The asslabel01combo and asslabel02combo are synthesized with an amino linker at their 5' termini to facilitate conjugation to reduced detector antibodies using the heterobifunctional cross linking reagent sulfo succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate.

Antibody Reduction

1ml of 1mg/ml anti-TSH monoclonal antibody was desalted/buffer exchange using PD10 columns pre equilibrated with 100mM sodium phosphate 5mM EDTA pH6.0. Positive fractions were pooled and concentrated (Sartorius 30kDa MWCO) to 1ml and added to 1 vial Perbio 2Mercaptoethyamine and incubated at 37°C for 90mins. The solution was concentrated (Sartorius 30kDa MWCO) to 500ul and applied to a PD10 column pre-equil with PBS 5mM EDTA pH7.0. Protein containing fractions were pooled and concentrated to 100ul.

Asslabelcombo S-SMCC treatment

250µl 1M sodium phosphate pH8.0 was added to 115µl water followed by 80µl of asslabelcombo(2mg/ml in water). 55µl of 1mg/ml S-SMCC was added and mixed thoroughly. The solution is vortexed and heated to 37°C for 20mins. The solution was applied to a PD10 column pre-equil with PBS pH7.0. Fractions containing the label were pooled and concentrated to 100µl using a Sartorius 3kDa MWCO column

Conjugation

The antibody and asslabelcombo solutions were pooled and incubated with agitation in the dark at room temp for 2hrs and overnight at 4°C

Protein G Purification

The 200µl was applied to a TBS pH8.5 pre-equilibrated Protein G column and eluted with 100mM glycine pH2.5. 1ml fractions were collected and assayed for protein using a BCA kit (Sigma) and oligonucleotide using OliGREEN. Positive fractions were pooled and concentrated to 200µl, aliquoted and stored at -20°C.

(iii) Coating of HyBaid Polycarbonate PCR plates**Binding Buffer**

42mg NaHCO₃ dissolved in 100ml deionised water, pH adjusted to 8.5

TBS/Tween

1.5g Trisma dissolved in 500ml of deionised water, pH adjusted to 7.4. 1.450g of NaCl added and 250µl of Tween-20

TBS-BLA

2g polypep, 10g beta-lactose, 100µg/ml salmon sperm DNA (from 10mg/ml frozen stock) added to 100ml TBS/Tween

Procedure

50µl of a solution containing 5µg/ml of anti-TSH and anti-HCG monoclonal antibodies in binding buffer was added to wells and incubated overnight at room temperature. Wells were washed three times with fresh TBS/Tween, using a BioHit plate washer. 150µl of TBS-BLA was added to wells and incubated for 1hr at room temperature. The wells were aspirated using the plate washer, drained and inverted to remove excess solution. The plates were air dried overnight.

(iv) Assay Procedure

25µl of TSH and HCG diluted in TBS, 2%pp, 2%BSA, 0.1% Tween was added to Hybaid coated wells and incubated for 1 hour at room temperature with agitation. The plate was washed 3 times with TBS-Tween using a BioHit plate washer. 25µl of anti-TSH-asslabelcombo1 and anti-HCG-asslabelcombo2 diluted in TBS, 2%pp, 2%BSA, 0.1% Tween was added to the wells and incubated for 1 hour at room temperature

with agitation. The plate was washed 3 times with TBS-Tween and 3 times with de-ionised water. 25 μ l of 10mM Tris pH8 was added to the wells which were then heated to 95°C for 5 minutes.

5 (v) PCR amplification and Melt Curve Analysis

PCR will be undertaken using the Roche Lightcycler. A reaction mix containing the following will be prepared.

	μ l
Sterile water ,	9.6
10 MgCl ₂	2.4
Palindromic primer final conc 0.2 μ M	2.0
FrameworkLabel01 final conc 0.2 μ M	1.0
FrameworkLabel03 final conc 0.2 μ M	1.0
Sensor/anchor hybridization probes	2.0

15

Mixed and pipetted into a precooled capillary. 2 μ l of denatured complex were added, the capillary capped and the reaction commenced (see Table 1)

(vi) Melt Curve Analysis

20

On completion of PCR, data for each sample is converted into melting point profiles by calculating the negative first derivative of the fluorescence $-dF/dt$ versus temperature. As the hybridization probes dissociate from the frameworkLabels 01 and 03 at 50.6°C and 62.3°C respectively two curves are simultaneously displayed. The area under the curve which correlates with the concentration is calculated from a Gaussian Fit curve. In this case the area under the first curve centred around 50°C correlates with the concentration TSH. The area under the second curve centred around 62°C correlates with the concentration of HCG.

25

30

Table 1

5

Program	Denaturation			
Seg No	Temp 'C	Hold Time sec	Slope C'/sec	Acquisition Mode
1	95	120	20	None
Program	Cycling			
Seg No				
1	95	3	20	None
2	62	4	20	Single
3	62	4	20	None
4	72	12	20	None
Program	Melting			
Seg No				
1	95	20	20	None
2	40	20	20	None
3	70		0.1	Continuous

Claims

- 5 1. An immuno polymerase chain reaction method to detect a plurality of biological molecules in a sample wherein said method comprises the steps of:
- i) providing a preparation comprising;
 - a) an assay sample to be tested; and
 - b) a plurality of ligands specific for at least one biological molecule in said assay
 - 10 sample wherein each ligand is coupled to an oligonucleotide;
 - ii) incubating said preparation under conditions which allow the binding of said ligands to said biological molecules to form a complex;
 - iii) adding to the first preparation a second preparation comprising;
 - a) a plurality of single stranded nucleic acid templates wherein said template
 - 15 molecules comprise a nucleic acid sequence which is modified by addition, deletion or substitution of at least one nucleic acid base wherein said modifications provide a plurality of templates which vary from one another such that the annealing temperatures of said templates to at least one detectable probe molecule is varied and which at least part of said
 - 20 template is adapted to anneal to the oligonucleotide of (b); and
 - b) at least one oligonucleotide primer and polymerase chain reaction reagents;
 - iv) conducting a polymerase chain reaction to amplify said template; and
 - v) conducting melt curve analysis during said reaction to determine the presence
 - 25 of said biological molecule.
- 2 A method according to Claim 1 wherein said assay sample selected from the group consisting of: blood; serum; semen; lymph fluid; cerebrospinal fluid; tears; saliva; urine; sweat.
- 30 3 A method according to Claim 1 wherein said sample is an environmental sample.

4. A method according to any of Claims 1-3 wherein said ligands are polypeptides.
5. A method according to Claim 4 wherein said polypeptides are antibodies, or
5 at least the effective binding part thereof.
6. A method according to Claim 5 wherein said antibodies are monoclonal antibodies, or at least the Fab fragment of said monoclonal antibody.
- 10 7. A method according to any of Claims 1-3 wherein said ligands are receptors.
8. A method according to any of Claims 1-7 wherein said biological molecules are associated with a cancer.
- 15 9. A method according to Claim 8 wherein molecule is a tumour rejection antigen.
10. A method according to any of Claims 1-7 wherein said biological molecule is a polypeptide expressed by a pathogen.
- 20 11. A method according to any of Claims 1-10 wherein said single stranded nucleic acid template comprises a conserved nucleic acid sequence each of which is modified by addition, deletion or substitution of at least one nucleic acid base wherein said modifications provide a plurality of probes which vary from one another such that the
25 annealing temperatures of said probes to a complementary sequence is varied.
12. A method according to any of Claims 1-11 wherein said detectable probe anneals to said template in a range of between 40 to 80°C.
- 30 13. A method according to Claim 12 wherein said annealing temperature is between 50 to 70°C.
- 14 A method according to any of Claims 1-13 wherein said detectable probe is a fluorescently labelled probe.

- 15 A method according to Claim 14 wherein said probe is a pair of fluorescently
labelled probes and detection is via fluorescence resonance energy transfer.
- 5 16. A method according to any of Claims 1-15 wherein said oligonucleotide
primer comprises a palindromic sequence.
- 10 17. A preparation comprising a plurality of single stranded nucleic acid template
molecules for use in the method according to any of claims 1 to 16, wherein said
molecules comprise a nucleic acid sequence which is modified by addition, deletion
or substitution of at least one nucleic acid base wherein said modifications provide a
plurality of templates which have altered annealing temperatures for at least one
single stranded nucleic acid molecule capable of annealing to said template.
- 15 18. A preparation according to Claim 17 wherein said composition further
includes at least one detectable probe molecule.
19. A preparation according to Claim 18 wherein said probe includes at least one
fluorescent label.
- 20 20 A kit comprising: a plurality of ligands; oligonucleotide molecules; a plurality
of nucleic acid templates according to any of claims 17 to 19; and a detectable
probe molecule(s).
- 25 21 A kit according to Claim 20 wherein said kit includes polymerase chain
reaction reagents.

Figure 1

FrameworkLabel101

Fwd

CCATAGTAACGCCAATACGCAnnnnnnnnnGGCTATTTCGGCTATGACTGGG
CCGATAAGCCGATACTGACCC

Rev

FrameworkLabel102

Fwd

GCCCAACCTGCCATCAGAGAnnnnnnnnnTAGCAGAACTCAGTTGGGC
TATCGTCTTGAGTCCAAACCCG

Rev

Figure 2

FrameworkLabel101

CCATAGTAACGCCAATACGCAnnnnnnnnnGGCTATTTCGGCTATGACTGGG

CCGATAAGCCGATACTGACCCACGCATAACCGCAATGATACC

asslabelcombo

FrameworkLabel102

GCCCAACCTGCCATCAGAGAnnnnnnnnnTAGCAGAACTCAGTTGGGC

TATCGTCTTGAGTCCAAACCCGAGAGCACTACCGTCCAACCCG

asslabelcombo

Figure 3

FrameworkLabel03

CCATAGTAACGCCAATACGCAnnnnnnnnATAGCAGAACTCAGGTTGGGC
TATCGTCTTGAGTCCAACCCGACGCATAAACCGCAATGATACC
asslabel02combo

Figure 4

InsertLabel01

agaagggtgtctgcgggagCcgaatttcacatcacgcagctttcttttgaggctgacacattcttcgcttt
Tm 50.6

sensor

anchor

InsertLabel02

agaagggtgtctgcgggagCcgaatttcacatcacgcagctttcttttgaggctgacacattcttcgcttt
Tm 62.3

Figure 5

AssembledLabel101

CCATAGTAACGCCAATACGCAGtggtgtgtggtggagGcgatttccatcgcagccttttttggaggctgacacattttGGCTATTCCGGCTATGACTGGG
CCGATAAGCCGATACTGACCCACGCATACCGCAATGATACC


Figure 6

AssembledLabel102

CCATAGTAACGCCAATACGCAGtggtgtgtggtggagCcgatttccatcgcagccttttttggaggctgacacattttATAGCAGAACTCAGTTGGGC
TATCGTCTTGAGTCCACCCGACGCATACCGCAATGATACC

Antibody Labels


Consist of (i) common 5' regions (1) and (ii) antibody specific 3' regions (2, 3, 4, 5)




Templates

Specific templates anneal to the antibody 3' regions of the labels.



Templates are highly conserved differing only by a few bases.




First cycle of PCR amplification results in the extension of the template and label to provide annealing sites for the palindromic primer.



Following the denaturation stage at the commencement of the 2nd PCR cycle both the palindromic primer and FRET probes bind the single strand template. Note the same primer and probes are used to bind all templates, only one example is shown



Melt curve analysis is performed after completion of cycling. A temperature gradient is applied and the 5' hybridisation probe becomes detached as its specific T_m is reached thus preventing signal generation by FRET.




Each template is designed to exhibit a unique T_m thereby enabling its identification for subsequent quantification


T_m 52°C




T_m 58°C




T_m 64°C




T_m 68°C



Schematic of Melt Curve Analysis of Four Templates of Differing T_m 

Melt Curve Analysis of Dilutions one template illustrating area under the curve



Areas which can be measured appear to correlate with initial template concentration

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB2004/000193

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 6 140 054 A (WITTEWER CARL T ET AL) 31 October 2000 (2000-10-31) claims 1-5; figures 13A,14,15; examples 5,8	17-19
A	---	1-16,20, 21
X	BERNARD P S ET AL: "HOMOGENEOUS MULTIPLEX GENOTYPING OF HEMOCHROMATOSIS MUTATIONS WITH FLUORESCENT HYBRIDIZATION PROBES" AMERICAN JOURNAL OF PATHOLOGY, PHILADELPHIA, PA, US, vol. 153, no. 4, 1998, pages 1055-1061, XP000874040 ISSN: 0002-9440	17-19
A	abstract; figure 4 --- -/-	1-16,20, 21

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

29 April 2004

Date of mailing of the international search report

04/06/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Knudsen, H

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB2004/000193

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BERNARD ET AL: "COLOR MULTIPLEXING HYBRIDIZATION PROBES USING THE APOLIPOPROTEIN E LOCUS AS A MODEL SYSTEM FOR GENOTYPING" ANALYTICAL BIOCHEMISTRY, ACADEMIC PRESS, SAN DIEGO, CA, US, vol. 273, no. 2, 10 September 1999 (1999-09-10), pages 221-228, XP000852429 ISSN: 0003-2697	17-19
A	abstract; figure 1D; table 1	1-16,20, 21
A	WO 01/31056 A (EL MOUALIJ BENAÏSSA ;ZORZI DANIELE (BE); ZORZI WILLY (BE); HEINEN) 3 May 2001 (2001-05-03) abstract; figures 16-19	1-16,20, 21
A	HENDRICKSON EDWIN R ET AL: "High sensitivity multianalyte immunoassay using covalent DNA-labeled antibodies and polymerase chain reaction" NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 23, no. 3, 1995, pages 522-529, XP002151883 ISSN: 0305-1048 the whole document	1-16,20, 21
A	WO 93/15229 A (DU PONT) 5 August 1993 (1993-08-05) page 26	16
P,X	WO 03/074733 A (HOPWOOD ANDREW JOHN ;SEC DEP FOR THE HOME DEPT (GB); WETTON JONATH) 12 September 2003 (2003-09-12) page 13-14	17
P,A	EP 1 375 674 A (TOSOH CORP) 2 January 2004 (2004-01-02) abstract; figure 3	1-16
P,A	WO 03/048388 A (FRASER WILLIAM DUNCAN ;GALLAGHER JAMES ANTHONY (GB); MCCREAVY DAVI) 12 June 2003 (2003-06-12) page 17-18; claims 25-28	1-21

INTERNATIONAL SEARCH REPORT

onal Application No
PCT/GB2004/000193

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 6140054	A	31-10-2000	AU 6280599 A EP 1117834 A1 JP 2002525128 T WO 0018965 A1	17-04-2000 25-07-2001 13-08-2002 06-04-2000
WO 0131056	A	03-05-2001	AU 1259801 A WO 0131056 A2 EP 1232283 A2	08-05-2001 03-05-2001 21-08-2002
WO 9315229	A	05-08-1993	AT 185378 T AU 3618593 A CA 2129444 A1 DE 69326685 D1 DE 69326685 T2 EP 0625211 A1 HK 1003719 A1 JP 7505765 T WO 9315229 A2	15-10-1999 01-09-1993 05-08-1993 11-11-1999 08-06-2000 23-11-1994 09-06-2000 29-06-1995 05-08-1993
WO 03074733	A	12-09-2003	WO 03074733 A2	12-09-2003
EP 1375674	A	02-01-2004	JP 2004024035 A EP 1375674 A1 US 2004014119 A1	29-01-2004 02-01-2004 22-01-2004
WO 03048388	A	12-06-2003	WO 03048388 A2	12-06-2003